Boston Scientific Warns Cyberattack to Hit Earnings Outlook

This is a notable case of cyber risk migrating from operational disruption to direct financial guidance, a shift that underscores how security incidents are now board-level earnings events. The lack of detail on the attack's scope leaves the market to price in uncertainty, which can be more damaging than a quantified hit. For the broader medtech and critical infrastructure sectors, this reinforces that cyber resilience is becoming a competitive and valuation factor, not just an IT concern. Whether Boston Scientific's recovery timeline and any regulatory or customer fallout emerge as the next chapter is the open question.